Trial site
John Theurer Cancer Center at Hackensack University Medical Center
- 36running trials
- 21closed trials
The trials here
What the 58 trials at this site are about, from their registry records.
- Conditions
- Lung cancer14 trials
- Acute myeloid leukaemia13 trials
- Multiple myeloma7 trials
- Melanoma5 trials
- Childhood cancers4 trials
- Colorectal cancer4 trials
- Myelodysplastic syndromes4 trials
- Diffuse large B-cell lymphoma3 trials
- Glioblastoma3 trials
- Metastatic breast cancer3 trials
- Prostate cancer3 trials
- Bladder cancer2 trials
- and 15 more
- Phase
- Phase 217 trials
- Phase 1/214 trials
- Phase 112 trials
- Phase 311 trials
- Early phase 11 trial
- Status
- Recruiting24 trials
- Terminated12 trials
- Active, not recruiting11 trials
- Completed8 trials
- Enrolling by invitation1 trial
- Suspended1 trial
- Withdrawn1 trial
- Lead sponsor
- Georgetown University9 trials
- Pfizer6 trials
- Bristol-Myers Squibb4 trials
- Celgene3 trials
- Hackensack Meridian Health3 trials
- and 25 more
Running trials
Recruiting
Recruiting
Recruiting
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Recruiting
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Recruiting
Recruiting
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Recruiting
Recruiting
Active, not recruiting
Recruiting
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Recruiting
Recruiting
Active, not recruiting
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Active, not recruiting
Active, not recruiting
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Enrolling by invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Active, not recruiting
Active, not recruiting
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Active, not recruiting
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Active, not recruiting
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Recruiting
Active, not recruiting
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Recruiting
Active, not recruiting
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer6 recruiting
- Acute myeloid leukaemia5 recruiting
- Metastatic breast cancer3 recruiting
- Childhood cancers2 recruiting
- Colorectal cancer2 recruiting
- Multiple myeloma2 recruiting
- Myelodysplastic syndromes2 recruiting
- Prostate cancer2 recruiting
- Acute lymphoblastic leukaemia1 recruiting
- Bladder cancer1 recruiting
- Endometrial cancer1 recruiting
- Glioblastoma1 recruiting
- Kidney cancer1 recruiting
- Liver and biliary tract cancer1 recruiting
- Melanoma1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Ovarian cancer1 recruiting
- Thymoma and thymic carcinoma1 recruiting
- Triple-negative breast cancer1 recruiting
Closed trials
Withdrawn
Terminated
Terminated
Completed
Terminated
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Terminated
Terminated
Terminated
Terminated
Terminated
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Completed
Terminated
Terminated
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Terminated
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Completed
Completed
Completed
Completed
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Terminated
Completed
Completed
Site data: ClinicalTrials.govUpdated 18 Nov 2026